Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X

Four with Medical School ties are among 12 University of Michigan faculty and staff members recognized by the American Association for the Advancement of Science (AAAS) as 2023 fellows in recognition of their extraordinary achievements.

A new urine-based test addresses a major problem in prostate cancer: how to separate the slow growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.

Four faculty and two staff members from the departments of Anesthesiology, Neurology, Radiology and Surgery, and the Office of Graduate Medical Education (GME), are recipients of GME Awards for 2024

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy

Michigan Medicine has developed a new technique that provides a non-invasive alternative to surgery, chemotherapy and radiation treatments for cancer.

Metabolism pathways make tumors sensitive or resistant to treatments. A collaborative group leverages these avenues to explore the growing foundation of new potential therapies

While it's tempting to know what's going on inside your entire body, a clinical perspective piece, written by a radiologist at the University of Michigan, discusses some of the harms of imaging low risk patients, such as overdiagnosis, overtreatment and their related complications

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

A study from clinicians and researchers at the University of Michigan Rogel Cancer Center reveals findings from over 800 clinical assays performed for kidney patients with MiTF family gene mutations.

There are 13 U-M graduate medical education programs ranked in the top 10 by Doximity.

An interview with Dr. Steven Kunkel on research at U-M Medical School.